Jan 16
Data Acquisition: The process for receipt of adverse event reports to the initial PV contact in the Company. The local intake process for all case types typically starts with acknowledgment of receipt, which is required in some instances (e.g., cases from business partners or clinical trials).
In 2020:
70% of respondents were applying at least some automation.
30% of respondents reported no automation of this ICSR process step.
In 2021:
78% of respondents were applying at least some automation.
22% of respondents reported no automation of this ICSR process step.
Related Blog Posts
Unifying Industry to Better Understand GCP Guidance
In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate…
Closing the Evidence Gap in Women’s Health – the Need for Inclusive Clinical Research
For decades, women were significantly underrepresented in clinical trials. Recent years have seen improvement, but there are lingering gaps in our collective understanding of how therapies work across sexes, life stages, health conditions and care settings. Read the full article by Jeneen Donadeo from PharmaTimes here.
Unsure About The New ICH Guidelines? TransCelerate Debuts 13 Tools To Help
If you’ve begun combing through the new ICH GCP E6(R3) guidelines to understand how the updates will affect your clinical research practices and feel just a little lost or overwhelmed, you’ve got help. TransCelerate BioPharma, in a partnership with the Association of Clinical Research Organizations (ACRO), has designed and released 13 tools to support E6(R3) adoption across…